These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 31311144)

  • 1. Quantitative Prediction of Human Pharmacokinetics and Pharmacodynamics of CKD519, a Potent Inhibitor of Cholesteryl Ester Transfer Protein (CETP).
    Choi S; Han S; Jeon S; Yim DS
    Pharmaceutics; 2019 Jul; 11(7):. PubMed ID: 31311144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative prediction of human pharmacokinetics and pharmacodynamics of imigliptin, a novel DPP-4 inhibitor, using allometric scaling, IVIVE and PK/PD modeling methods.
    Liu D; Ma X; Liu Y; Zhou H; Shi C; Wu F; Jiang J; Hu P
    Eur J Pharm Sci; 2016 Jun; 89():73-82. PubMed ID: 27108678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Translational prediction of first-in-human pharmacokinetics and pharmacodynamics of janagliflozin, a selective SGLT2 inhibitor, using allometric scaling, dedrick and PK/PD modeling methods.
    Song L; Yao X; Liu Y; Zhong W; Jiang J; Liu H; Zhou H; Shi C; Zong K; Wang C; Ma C; Liu D; Hu P
    Eur J Pharm Sci; 2020 Apr; 147():105281. PubMed ID: 32126254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Population Pharmacokinetic and Pharmacodynamic Model of CKD-519.
    Kim CO; Jeon S; Han S; Park MS; Yim DS
    Pharmaceutics; 2020 Jun; 12(6):. PubMed ID: 32575566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Predict the Impact of CYP2C9 Genetic Polymorphisms, Co-Medication and Formulation on the Pharmacokinetics and Pharmacodynamics of Flurbiprofen.
    Loisios-Konstantinidis I; Cristofoletti R; Jamei M; Turner D; Dressman J
    Pharmaceutics; 2020 Nov; 12(11):. PubMed ID: 33147873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pre-clinical quantitative model predicts the pharmacokinetics/pharmacodynamics of an anti-BDCA2 monoclonal antibody in humans.
    Biliouris K; Nestorov I; Naik H; Dai D; Xiao G; Wang Q; Pellerin A; Rabah D; Lesko LJ; Trame MN
    J Pharmacokinet Pharmacodyn; 2018 Dec; 45(6):817-827. PubMed ID: 30377889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Translational PK/PD Modeling of Tumor Growth Inhibition and Target Inhibition to Support Dose Range Selection of the LMP7 Inhibitor M3258 in Relapsed/Refractory Multiple Myeloma.
    Lignet F; Esdar C; Walter-Bausch G; Friese-Hamim M; Stinchi S; Drouin E; El Bawab S; Becker AD; Gimmi C; Sanderson MP; Rohdich F
    J Pharmacol Exp Ther; 2023 Jan; 384(1):163-172. PubMed ID: 36273822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Translational and pharmacokinetic-pharmacodynamic application for the clinical development of GDC-0334, a novel TRPA1 inhibitor.
    Chan P; Ding HT; Liederer BM; Mao J; Belloni P; Chen L; Gao SS; Joseph V; Yang X; Lin JS; Mitra MS; Putnam WS; Quartino A; Bauer RN; Pan L
    Clin Transl Sci; 2021 Sep; 14(5):1945-1954. PubMed ID: 34058071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical Pharmacokinetics and Translational Pharmacokinetic/Pharmacodynamic Modeling of M8891, a Potent and Reversible Inhibitor of Methionine Aminopeptidase 2.
    Lignet F; Friese-Hamim M; Jaehrling F; El Bawab S; Rohdich F
    Pharm Res; 2023 Dec; 40(12):3011-3023. PubMed ID: 37798538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined translational pharmacometrics approach to support the design and conduct of the first-in-human study of DWP16001.
    Lee SJ; Bae SH; Jeon S; Ji HY; Han S
    Br J Clin Pharmacol; 2024 Jan; 90(1):286-298. PubMed ID: 37602795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Translational PK-PD modeling analysis of MCLA-128, a HER2/HER3 bispecific monoclonal antibody, to predict clinical efficacious exposure and dose.
    de Vries Schultink AHM; Doornbos RP; Bakker ABH; Bol K; Throsby M; Geuijen C; Maussang D; Schellens JHM; Beijnen JH; Huitema ADR
    Invest New Drugs; 2018 Dec; 36(6):1006-1015. PubMed ID: 29728897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanistic prediction of first-in-human dose for bispecific CD3/EpCAM T-cell engager antibody M701, using an integrated PK/PD modeling method.
    Song L; Xue J; Zhang J; Li S; Liu D; Zhou T
    Eur J Pharm Sci; 2021 Mar; 158():105584. PubMed ID: 33039565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DallphinAtoM: Physiologically based pharmacokinetics software predicting human PK parameters based on physicochemical properties, in vitro and animal in vivo data.
    Choi S; Han S; Lee SJ; Lim B; Bae SH; Han S; Yim DS
    Comput Methods Programs Biomed; 2022 Apr; 216():106662. PubMed ID: 35151112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical drug metabolism and pharmacokinetics, and prediction of human pharmacokinetics and efficacious dose of the investigational Aurora A kinase inhibitor alisertib (MLN8237).
    Yang JJ; Li Y; Chakravarty A; Lu C; Xia CQ; Chen S; Pusalkar S; Zhang M; Ecsedy J; Manfredi MG; Wu JT; Shyu WC; Balani SK
    Drug Metab Lett; 2014 Jul; 7(2):96-104. PubMed ID: 24484538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of human pharmacokinetics of activated recombinant factor VII and B-domain truncated factor VIII from animal population pharmacokinetic models of haemophilia.
    Larsen MS; Juul RV; Groth AV; Simonsson USH; Kristensen AT; Knudsen T; Agersø H; Kreilgaard M
    Eur J Pharm Sci; 2018 Mar; 115():196-203. PubMed ID: 29369801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interspecies scaling of receptor-mediated pharmacokinetics and pharmacodynamics of type I interferons.
    Kagan L; Abraham AK; Harrold JM; Mager DE
    Pharm Res; 2010 May; 27(5):920-32. PubMed ID: 20232116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of a potentially effective dose in humans for BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein (CETP) by allometric species scaling and combined pharmacodynamic and physiologically-based pharmacokinetic modelling.
    Weber O; Willmann S; Bischoff H; Li V; Vakalopoulos A; Lustig K; Hafner FT; Heinig R; Schmeck C; Buehner K
    Br J Clin Pharmacol; 2012 Feb; 73(2):219-31. PubMed ID: 21762205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiologically-based pharmacokinetic/pharmacodynamic modeling to predict tumor growth inhibition and the efficacious dose of selective estrogen receptor degraders in humans.
    Ganti A; Yu S; Sharpnack D; Ingalla E; De Bruyn T
    Biopharm Drug Dispos; 2023 Aug; 44(4):301-314. PubMed ID: 37102506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shared learning from a physiologically based pharmacokinetic modeling strategy for human pharmacokinetics prediction through retrospective analysis of Genentech compounds.
    Mao J; Ma F; Yu J; Bruyn T; Ning M; Bowman C; Chen Y
    Biopharm Drug Dispos; 2023 Aug; 44(4):315-334. PubMed ID: 37160730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population Pharmacokinetics (PK) and Pharmacodynamics (PD) Analysis of LY3015014, a Monoclonal Antibody to Protein Convertase Subtilisin/Kexin Type 9 (PCSK9) in Healthy Subjects and Hypercholesterolemia Patients.
    Shen T; James DE; Krueger KA
    Pharm Res; 2017 Jan; 34(1):185-192. PubMed ID: 27822850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.